Gamida Cell, the Jerusalem specialist in stem-cell technologies to treat cancer and genetic diseases, received a $4.4 million grant from the Israel Innovation Authority, formerly the Office of the Chief Scientist. The non-dilutive funding will support R&D, including Gamida Cell’s Phase III registration study of NiCord for blood cancers like leukemia and lymphoma, and its clinical trials of CordIn for sickle-cell disease and thalassemia.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: